BR100 Increased By (0.8%)
BR30 Increased By (0.66%)
KSE100 Increased By (0.63%)
KSE30 Increased By (0.63%)
AGHA 7.80 Increased By ▲ 0.05 (0.65%)
BECO 5.19 No Change ▼ 0.00 (0%)
BML 57.93 Decreased By ▼ -0.73 (-1.24%)
BOP 34.25 Increased By ▲ 0.56 (1.66%)
CNERGY 10.95 Increased By ▲ 0.34 (3.2%)
CSIL 5.45 Increased By ▲ 0.15 (2.83%)
FCCL 54.60 Increased By ▲ 0.86 (1.6%)
FFL 16.67 Increased By ▲ 0.21 (1.28%)
FNEL 1.24 Increased By ▲ 0.02 (1.64%)
KEL 7.40 Increased By ▲ 0.12 (1.65%)
KOSM 5.78 Increased By ▲ 0.14 (2.48%)
LOTCHEM 29.82 Increased By ▲ 0.17 (0.57%)
MLCF 95.75 Decreased By ▼ -0.61 (-0.63%)
NBP 204.90 Increased By ▲ 1.37 (0.67%)
NCPL 57.73 Increased By ▲ 0.88 (1.55%)
NPL 69.22 Increased By ▲ 1.91 (2.84%)
OGDC 318.39 Increased By ▲ 0.17 (0.05%)
PACE 10.83 Increased By ▲ 0.20 (1.88%)
PAEL 43.00 Increased By ▲ 1.23 (2.94%)
PIBTL 16.83 Increased By ▲ 0.02 (0.12%)
PPL 221.70 Increased By ▲ 1.53 (0.69%)
PRL 52.05 Increased By ▲ 3.00 (6.12%)
PTC 71.25 Increased By ▲ 1.24 (1.77%)
SSGC 29.25 Increased By ▲ 0.11 (0.38%)
TBL 9.88 Increased By ▲ 0.11 (1.13%)
TELE 8.88 Increased By ▲ 0.06 (0.68%)
TPL 17.72 Increased By ▲ 0.55 (3.2%)
TPLP 12.89 Increased By ▲ 0.38 (3.04%)
TREET 22.81 Increased By ▲ 0.22 (0.97%)
TRG 60.04 Decreased By ▼ -0.18 (-0.3%)
Markets

Philips reports 3% rise in quarterly sales

Published Updated
By

Dutch medical technology company Philips reported third-quarter revenue in line with analysts’ expectations un Tuesday, citing a strong performance in North America.

The company posted a 3% rise in sales to 4.3 billion euros ($5.0 billion), matching analysts’ average estimate in a company-compiled poll.

Philips, which makes the biggest share of its revenue in the United States, flagged last quarter that tariffs would have a lower impact than expected following a trade agreement between the EU and United States.

Its adjusted earnings before interest, tax and amortisation (EBITA) came in at 531 million euros, surpassing the 484 million expected by analysts.

Comments

Comments are closed for this article.